Diffusion Weighted Magnetic Resonance Imaging for the Characterization of Solitary Pulmonary Lesions (DWIMRICSPL)

June 25, 2015 updated by: ÇAĞLAYAN ÇAKIR
The purpose of this study, is to investigate the value of diffusion weighted imaging on the differential diagnosis of solitary pulmonary lesions.

Study Overview

Status

Completed

Conditions

Detailed Description

When a patient is diagnosed with a lung lesion, the differential diagnosis is important, since the treatment is determined by the lesion character. The goal in the evaluation of solitary pulmonary lesions is to distinguish malignant lesions from benign lesions in as non-invasive a manner as possible. As computed tomography is widely used, the diagnosis of solitary pulmonary lesions has become easier. The size, features of the edges, shape, internal structure (calcification, fat content, cavitation, etc.), density, satellite nodule, growth rate and contrast involvement of the lesion are important properties which help to distinguish benign lesions from malignant ones. However, as the distinction is not absolute at all times, other imaging methods such as positron emission tomography and magnetic resonance are preferred. The importance of this issue is the high five-year survival rate in early-diagnosed lung cancer cases.

Diffusion is the randomized microscopic motion of water molecules. It is known that diffusion is a sensitive parameter of tissue characterization at a microscopic level. Nowadays, diffusion is measured in vivo with diffusion weighted MRI and ADC measurements.

Diffusion weighted imaging has a wide use on oncologic patients for the purpose of diagnosis. In addition, it is used in the distinction of acute cerebral infarction and epidermoid or arachnoid cysts. Recently, it has also been used in the characterization of cystic or solid lesions in the thoracic cavity. In this study, the investigators aimed to evaluate the accuracy of differentiation of solitary pulmonary lesions.

Study Type

Observational

Enrollment (Actual)

46

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Edi̇rne, Turkey, 22400
        • Trakya University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 78 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Magnetic resonance imaging (MRI) was applied to a total of 46 patients between January 2011 and July 2011, who presented.

Description

Inclusion Criteria:

  • All patients had a solitary pulmonary nodule or mass.

Exclusion Criteria:

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
On diffusion weighted images, the signal intensities of the lesions were visually compared to the SI of the thoracic spinal cord using a 5-point scale.
Time Frame: 1 year
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: HAKAN GENÇHELLAÇ, MD, TURKEY,EDİRNE ,TRAKYA UNİVERSİTY HOSPİTAL

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2011

Primary Completion (Actual)

December 1, 2011

Study Completion (Actual)

December 1, 2011

Study Registration Dates

First Submitted

June 19, 2015

First Submitted That Met QC Criteria

June 25, 2015

First Posted (Estimate)

June 26, 2015

Study Record Updates

Last Update Posted (Estimate)

June 26, 2015

Last Update Submitted That Met QC Criteria

June 25, 2015

Last Verified

June 1, 2015

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • TRAKYA22

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Thorax Cancer

3
Subscribe